🇺🇸 FDA
Patent

US 8580735

Local complement inhibition for treatment of complement-mediated disorders

granted A61KA61K38/12A61K38/17

Quick answer

US patent 8580735 (Local complement inhibition for treatment of complement-mediated disorders) held by Apellis Pharmaceuticals, Inc. expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/12, A61K38/17, A61K39/3955, A61K45/06